Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News DermTech Inc DMTKQ

Healthcare Biotechnology
DermTech, Inc. is a molecular diagnostic company. The Company is engaged in developing and marketing non-invasive genomics tests to aid in the diagnosis and management of melanoma. Its technology enhances evaluation of lesions suspicious for melanoma using non-invasive sample collection and detecting genomic markers associated with melanoma to identify higher risk lesions or rule out melanoma... see more

Recent & Breaking News (OTCPK:DMTKQ)

CMS Releases Final 2020 Clinical Lab Fee Schedule (CLFS) Including Pricing for DermTech's Pigmented Lesion Assay (PLA)

Business Wire January 8, 2020

DermTech's Pigmented Lesion Assay (PLA) Receives Medicare Coverage

Business Wire January 2, 2020

DermTech, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Business Wire November 7, 2019

DermTech to Present at Upcoming Investor Conferences

Business Wire November 6, 2019

DermTech Receives CPT® Proprietary Laboratory Assay Code from the American Medical Association

Business Wire October 28, 2019

DermTech Presents New Data at Fall Clinical Dermatology Conference

Business Wire October 22, 2019

DermTech Announces Common Stock Will Continue Trading on The Nasdaq Capital Market; Warrant Delisting from The Nasdaq Capital Market

Business Wire October 18, 2019

DermTech's Test Included in Expert Panel's Clinical Management Recommendations for Cutaneous Melanoma

Business Wire October 15, 2019

DermTech Further Expands Patent Portfolio

Business Wire October 7, 2019

DermTech Announces Appointment of Kevin Sun as Chief Financial Officer

Business Wire September 16, 2019

DermTech Announces Successful Closing of Business Combination with Constellation Alpha Capital Corp.

Business Wire September 3, 2019

Constellation Alpha Capital Corp. Announces Successful Closing of Business Combination With DermTech

Business Wire August 30, 2019

Constellation Alpha Capital Corp. to Merge with DermTech, Inc., a leading innovator of genomics for dermatology and non-invasive skin cancer diagnosis

PR Newswire May 29, 2019

Constellation Alpha Capital Corp. Signs Letter of Intent to Acquire DermTech, Inc., a leading innovator of genomics for dermatology and non-invasive skin cancer diagnosis

PR Newswire March 15, 2019

Constellation Alpha Capital Corp. to Acquire Medall Healthcare Private Limited, one of India's Largest Integrated Pathology and Radiology Companies

PR Newswire August 2, 2018

Constellation Alpha Capital Corp. Announces Separate Trading of its Ordinary Shares, Rights and Warrants, Commencing August 10, 2017

PR Newswire August 9, 2017

Constellation Alpha Capital Corp. Completes Initial Public Offering

PR Newswire June 23, 2017

Constellation Alpha Capital (Nasdaq: CNACU) to Ring The Nasdaq Stock Market Closing Bell

GlobeNewswire June 21, 2017